Lower risk for cardiovascular mortality in oral 1 -hydroxy vitamin D3 users in a haemodialysis population

Abstract

These results indicate that use of oral alfacalcidol was associated with reduced risk for cardiovascular death in this cohort of ESRD patients. The result of this observational study warrants further randomized controlled trials with 1alpha-hydroxy vitamin D3 to confirm the possibility that such medication improves survival of ESRD patients.